LEFLUNOMIDE

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category UNKNOWN
ATC L04AA13
UNII G162GK9U4W
EPA CompTox DTXSID9023201

Structure

InChI Key VHOGYURTWQBHIL-UHFFFAOYSA-N
Smiles Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1
InChI
InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

Physicochemical Descriptors

Property Name Value
Molecular Formula C12H9F3N2O2
Molecular Weight 270.21
AlogP 3.25
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 2.0
Polar Surface Area 55.13
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 19.0

Bioactivity

Mechanism of Action Action Reference
Dihydroorotate dehydrogenase inhibitor INHIBITOR DailyMed
Protein: Dihydroorotate dehydrogenase
Description: Dihydroorotate dehydrogenase (quinone), mitochondrial
Organism : Homo sapiens
Q02127 ENSG00000102967
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - -
Enzyme Oxidoreductase
- 10000-13000 - - 12
Epigenetic regulator Writer Protein methyltransferase SET domain
- - - - 4
Assay Description Organism Bioactivity Reference
Inhibition of beta-lactamase at 100 uM None 5.0 %
Inhibition of chymotrypsin at 250 uM unidentified 5.0 %
Inhibitory concentration tested on enzyme dihydroorotate dehydrogenase in mouse None 30.0 nM
Inhibitory concentration tested against enzyme dihydroorotate dehydrogenase in rat None 9.0 nM
Inhibition of malate dehydrogenase (MDH) at 400 uM None 12.0 %
In vivo inhibition of TNP-specific immunoglobulin G production at 10 mg/kg/day oral administration. Mus musculus 0.0 %
In vivo inhibition of TNP-specific immunoglobulin G production at 3 mg/kg/day subcutaneous administration. Mus musculus 0.0 %
In vivo inhibition of TNP-specific immunoglobulin G production at 30 mg/kg/day subcutaneous administration. Mus musculus 39.0 %
In vivo inhibition of TNP-specific immunoglobulin G production at 50 mg/kg/day subcutaneous administration. Mus musculus 85.0 %
In vivo inhibition of TNP-specific immunoglobulin M production at 10 mg/kg/day, po Mus musculus 5.0 %
In vivo inhibition of TNP-specific immunoglobulin M production at 3 mg/kg/day, sc Mus musculus 0.0 %
In vivo inhibition of TNP-specific immunoglobulin M production at 30 mg/kg/day, sc Mus musculus 37.0 %
In vivo inhibition of TNP-specific immunoglobulin M production at 50 mg/kg/day, sc Mus musculus 71.0 %
Inhibition of paw edema formation in mouse after an peroral dose of 10 mg/kg; Thickness of paw =2.45+/-0.14 mm Mus musculus 45.0 %
In vivo for its ability to inhibit delayed type hypersensitivity in mouse following 30 mg/kg administration. Mus musculus 84.0 %
In vivo for its ability to inhibit delayed type hypersensitivity in mouse following 10 mg/kg administration. Rattus norvegicus 78.0 %
Inhibition of human FAAH at 1 uM Homo sapiens -5.67 %
PUBCHEM_BIOASSAY: Counter Screen for Luciferase-based Assay Positives. (Class of assay: confirmatory) [Related pubchem assays: 620, 618, 411 ] Photinus pyralis 840.0 nM
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) None 500.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 15.79 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.25 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.25 %
Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control Homo sapiens 4.0 %
Inhibition of human DHODH Homo sapiens 800.0 nM

Cross References

Resources Reference
ChEBI 6402
ChEMBL CHEMBL960
DrugBank DB01097
DrugCentral 1552
FDA SRS G162GK9U4W
Human Metabolome Database HMDB0015229
Guide to Pharmacology 6825
KEGG C07905
PharmGKB PA450192
PubChem 3899
SureChEMBL SCHEMBL5057
ZINC ZINC000000004840
CONTENTS